Steven J. O'Day, MD | Authors

1200 S YORK ST


Update on Adjuvant Interferon Therapy for High-Risk Melanoma

September 01, 2002

Despite more than 2 decades of active clinical study, the use of interferon as adjuvant therapy for high-risk melanoma remains controversial. The controversy has centered on dose, schedule, and toxicity of treatment. Agarwala and Kirkwood superbly summarize the clinical studies to date and highlight many of the salient issues relevant to clinicians.

Thalidomide-Induced Cessation of Weight Loss and Improved Sleep in Advanced Cancer Patients With Cachexia

November 01, 2000

The cachexia of malignancy is considered mediated through excess production of tumor necrosis factor–alpha and other cytokines. Thalidomide (Thalomid), a sedative/hypnotic, has been shown to inhibit tumor necrosis factor–alpha production.